Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

Novartis selects Quantum for eczema drug

Published on .

Novartis Pharmaceuticals Corp., East Hanover, N.J., tapped CommonHealth's Quantum Group, Parsippany, N.J., to handle consumer promotions for a still-in-development eczema drug known as SDZ ASM 981. Another CommonHealth arm, Noesis Healthcare Interactions, will handle promotions aimed at healthcare professionals. The drug is billed as a revolution in the treatment of eczema, a common skin disorder.

Copyright November 2000, Crain Communications Inc.

Most Popular
In this article: